Pseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have
early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2
clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in
pseudohypoparathyroidism. The investigators hypothesize that theophylline will cause weight
loss, improve glucose tolerance and slow growth plate closure in children and young adults.